Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Completed · Phase 2 · Has a placebo group

Conditions studied: Prurigo Nodularis, Pruritis

In brief

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).

Key facts

Study ID
NCT03816891
Run by
Genentech, Inc.
People needed
240
Starts
2019-03-11
Expected to finish
2023-08-24
Last updated by the study team
2026-01-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.